A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 476 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests May 23, 2018 PROs Support Switching to Camizestrant Plus CDK4/6 Inhibitor for HR-positive, HER2-negative... November 10, 2025 EMA Recommends Granting a Marketing Authorisation for Generic Eribulin January 12, 2024 Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Load more HOT NEWS EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib Using Technology to Find Cancers Early and Exercise Improves Sexual Health... Nurse Diagnosed with Stage IV Cancer After Thinking Her Pain Was... Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint...
